Pharmaceuticals announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the ...

Pharmaceuticals announced the pricing of an underwritten public offering of 13,158,000 shares of its common stock at a public ...

The stock's rise snapped a four-day losing streak.

US biotech Inovio (Nasdaq: INO) said it plans to offer and sell shares of its common stock in an underwritten public offering ...

Inovio Pharmaceuticals Inc. INO) on Monday reported a loss of $45.5 million in its third quarter.

Investing.com -- INOVIO Pharmaceuticals Inc. (NASDAQ:INO) shares fell 10% after the biotechnology company announced the pricing of an underwritten public offering at $1.90 per share, representing a ...

Completed rolling Biologics License Application (BLA) submission seeking accelerated approval for lead candidate INO-3107; requested priority review ...

The biotech sector has long offered investors high-risk, high-reward stocks. While large players are making headlines, the ...

INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and ...

Shares of Inovio Pharmaceuticals Inc. INO shed 2.88% to $2.36 Thursday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ Composite Index COMP falling 1.57 ...

The study tests two interventions: Inotuzumab Ozogamicin, an experimental drug targeting CD22-positive B-cell precursor ALL, and the ALLR3 regimen, a standard chemotherapy treatment. Inotuzumab ...

SHELTON, CONNECTICUT / ACCESS Newswire / November 11, 2025 / NanoViricides, Inc. (the "Company"), today announced that it has entered into a securities purchase agreement with a single healthcare ...